Este lanzamiento, desarrollado y registrado por Samsung Bioepis, se convierte en uno de los primeros biosimilares de ustekinumab. El tratamiento está indicado para adultos con psoriasis en placas, artritis psoriásica, enfermedad de Crohn y psoriasis pediátrica en placas en pacientes niños y adolescentes de seis años o más.
Pruritus is the main symptom of many dermatologic and systemic diseases. Atopic dermatitis, psoriasis, contact dermatitis, urticaria, lichen simplex chronicus, mycosis fungoides, scars, autoimmune diseases, kidney or liver diseases among others are all associated with […]
Background and objective Real-world evidence of paediatric psoriasis (PsO) is lacking in Spain. The purpose of this study was to identify physician-reported disease burden and current treatment patterns in a real-world paediatric PsO patient cohort […]
